{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "document_metadata": {
      "authors": "Esther Wollert",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Chronic Anatabine Treatment Reduces Alzheimer ’ s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "PUBCHEM": "^\\d+$",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns",
      "FB": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/rgd-names.belns"
    },
    "namespaces_uncached": [],
    "path": "anatabine/verma2015.bel",
    "pybel_version": "0.13.2"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " We have shown previously that anatabine displays some anti-inflammatory properties and reduces microgliosis and tau phosphorylation in a pure mouse model of tauopathy.",
      "key": "2869493e0e636f294fc004e9fe943c2ae7190acf69e6d0544ef699ceab47dbb69afb6b2d6367deba2914203693b9b96cbaaffd2140789b895aa01b2b99f93321",
      "line": 80,
      "relation": "decreases",
      "source": 1,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have shown previously that anatabine displays some anti-inflammatory properties by reducing the activation of NFκB and STAT3 [17,18].",
      "key": "21664787b63aca8dd35547cc98555a9fefa23f969c7fab3db224df1224b974b08f64977227c2d461a14f06918c4f80c8914701e347d8146e55a6366a4a002e97",
      "line": 99,
      "relation": "decreases",
      "source": 1,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have previously shown that anatabine inhibits STAT3 and NFκB activation [18] resulting in decreased neuroinflammation in a mouse model of multiple sclerosis.",
      "key": "d78fe112a74186fc7eb572de3a133467b15a80dc1bc7e17abdacc22f88c30c13eca334e866cc3332a8586a08a00ca8d44a8a4fd39b076882cbe4852606cb4185",
      "line": 215,
      "relation": "decreases",
      "source": 1,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " We have shown previously that anatabine displays some anti-inflammatory properties and reduces microgliosis and tau phosphorylation in a pure mouse model of tauopathy.",
      "key": "77ef1ae5d683637913f131f3b9e651b5d933db47a21ec1a2da854be1f20e50116da958cc347e94aa0b4017edd608606b7913e524bfb73db6911abe06186378ec",
      "line": 81,
      "relation": "decreases",
      "source": 1,
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " We have shown previously that anatabine displays some anti-inflammatory properties and reduces microgliosis and tau phosphorylation in a pure mouse model of tauopathy.",
      "key": "feceac31ac30b111adf077d83d7f7b12b1175b909e3093972bdeb77b63b18575da61bd9bedd73beb37f008293c573e71b8255b102c9133be343de0c63f79774f",
      "line": 83,
      "relation": "decreases",
      "source": 1,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Anatabine has a chemical structure closely related to nicotine and is a full agonist of α7 and α4β2 nicotinic acetylcholine receptors (nAChR) but is a more potent α7 nAChR agonist than nicotine [15,16].",
      "key": "8ee77b807b642a85ef1eba387bfba38aa60fbc5d90a5c50299af32841cfca31c868de2dd4802ec9af87ddd19f612fb4ad84a696e52b5f6266c873ea1494f98d7",
      "line": 92,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 1,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have shown previously that anatabine displays some anti-inflammatory properties by reducing the activation of NFκB and STAT3 [17,18].",
      "key": "63c9cca75f67ce4af01c97e390291b782f36d562901feb4391aa07941572f8d3d211070da0400016eda2c334b4332c88a2abe0350dc4e8ac1badc5ea740d6e6e",
      "line": 100,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have previously shown that anatabine inhibits STAT3 and NFκB activation [18] resulting in decreased neuroinflammation in a mouse model of multiple sclerosis.",
      "key": "640b5687fa32752b232adbd4be08af9803ed7280d6c9b932f32c280db59e25a1447a4d912903dd00eb6f77a201aaf692ca9b25961808fa7dcbce8110f67d0c93",
      "line": 212,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Interestingly, we found a significant reduction in the expression of amyloid plaque associated phospho-p65 NFκB immunopositive cells in Tg PS1/APPswe mice treated with anatabine at either 10 or 20 mg/Kg/Day (Fig 7B) showing that anatabine prevents NFκB activation in the brain of Tg PS1/APPswe mice.",
      "key": "a35e2ccbf83b229e94796ea801ecc3fdae8afeb695387aae01610bc5ed5814839d7c87be95cf5cff72ffaf8d2570d24c6bb7c83523ff7764379bc143da069c62",
      "line": 268,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have shown previously that anatabine displays some anti-inflammatory properties by reducing the activation of NFκB and STAT3 [17,18].",
      "key": "2ad76403e1c48f4e478f0110ad31398cafe455aeb21cfb39a4b36e9b107b44d257fc16bc39c846bdc59cb3b571fa50f1c9e188a14a2b91f8d24fa190bdc3a2a4",
      "line": 101,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We have previously shown that anatabine inhibits STAT3 and NFκB activation [18] resulting in decreased neuroinflammation in a mouse model of multiple sclerosis.",
      "key": "d05f9c29d86498b724d3575f406a436f298d673a713469c3fdbc7444abfbbce95be4b0b8257d56dfe9bee0b5a57c5e204f1370c07c08791b42e8d51c48b38852",
      "line": 213,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "A significant reduction in STAT3 phosphorylation was observed in the hippocampus and cortex of Tg PS1/APPswe mice treated with 10 or 20 mg/Kg/Day of anatabine compared to Tg PS1/APPswe receiving regular drinking water (Fig 6B) showing that anatabine prevents STAT3 activation in the brain of Tg PS1/APPswe mice. ",
      "key": "2e23cdf1f77b6c68e3ddeca85815af0d41f0b7f542937bec5dd95504cc73e733367f2745371636df8a79846e67bf341a003b911cad211e45ee2129dcf686d78f",
      "line": 241,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 1,
      "target": 12
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Interestingly, the hyper- active behavior of Tg PS1/APPswe mice was suppressed with the anatabine treatment at a dos- age of 20 mg/Kg/Day (Fig 2B and 2C). ",
      "key": "83d74746ca3ae69da6cb050897b1549f7ef25db3818d953385c8da44ce081fe1a73eb22763cddd36a85a7ef43afa4ba8babd91177b07c34b872406aa6e06433c",
      "line": 121,
      "relation": "decreases",
      "source": 1,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "The disinhibition affecting Tg PS1/APPswe mice was suppressed following treatment with anatabine at a dosage of either 10 or 20 mg/Kg/Day at both the time points (Figs 2D and 3D).",
      "key": "430892c059028c04ce80e7f41c3bb0790a0f5c17fd640ec7918f6be22d89a871ea8e7724ebae4f9273913f6d482bc65c1fcd5b11c77cc188e282eed93a07fb07",
      "line": 131,
      "relation": "decreases",
      "source": 1,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Unlike wild-type mice, Tg PS1/APPswe mice elicited social interaction deficits and spent an equal amount of time in the chamber containing the empty cage or the chamber containing the unfamiliar (Stranger 1) mouse (Fig 4A). Anatabine at a dosage of 20mg/Kg/Day restored sociability in Tg PS1/APPswe mice as Tg PS1/APPswe mice treated with anatabine spent significantly more time in the chamber containing the unfamiliar mouse (Stranger 1) and less time in the chamber containing the empty cage (Fig 4B).",
      "key": "790bfbee421a059fa57e7bd37fbd9b48f5a0acde8f113991e77e7c1f4e2472d098c96f9ad3fbd1302ea8956e805b5cb60c3bc910a5f59fd7ca7917f01464c235",
      "line": 145,
      "relation": "increases",
      "source": 1,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Interestingly, Tg PS1/APPswe mice treated with anata- bine at a dosage of 20 mg/Kg/Day, but not 10mg/Kg/day showed a significant reduction in Iba- 1 burden in the hippocampus compared to untreated Tg PS1/APPswe mice (Fig 5A and 5B), suggesting that anatabine suppresses microgliosis in the brain of Tg PS1/APPswe mice.",
      "key": "45d1c00a5aa69e58f0a251c9c38f94d8c3c104c959295eb775ccf17037f6beb8fa63d0acbe8d183921cc619f595189584c61ce1d0b2f0fd076f0a1f7b653de7e",
      "line": 172,
      "relation": "decreases",
      "source": 1,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Interestingly, Tg PS1/APPswe mice treated with anata- bine at a dosage of 20 mg/Kg/Day, but not 10mg/Kg/day showed a significant reduction in Iba- 1 burden in the hippocampus compared to untreated Tg PS1/APPswe mice (Fig 5A and 5B), suggesting that anatabine suppresses microgliosis in the brain of Tg PS1/APPswe mice.",
      "key": "66aa0c74a49778156e1b5252d1fd434a08e52ae5e090eaae9a1ef4b073853ac2b625937815dacbc845624c30971cb967c8b486b43ce969cc9f38cde580579d7f",
      "line": 173,
      "relation": "decreases",
      "source": 1,
      "target": 3
    },
    {
      "annotations": {
        "Cell": {
          "macrophage": true,
          "microglial cell": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " However, we observed a significant reduction in CD45 immunopositive microglia/macrophage in Tg PS1/APPswe mice receiving anatabine at a dosage of 10 and 20 mg/Kg/Day compared to Tg PS1/APPswe mice receiving regular drink- ing water (Fig 5C and 5D).",
      "key": "e9a37f3097f616cd91445b57baab8ff53237fbdcfadf1476734b64290f9b8a80f4ee22ca3dc40c8a31c19f83c357c49776aa8f537ee7cd5850ac3712179e9c7c",
      "line": 202,
      "relation": "decreases",
      "source": 1,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true,
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "A significant reduction in STAT3 phosphorylation was observed in the hippocampus and cortex of Tg PS1/APPswe mice treated with 10 or 20 mg/Kg/Day of anatabine compared to Tg PS1/APPswe receiving regular drinking water (Fig 6B) showing that anatabine prevents STAT3 activation in the brain of Tg PS1/APPswe mice. ",
      "key": "89f466f1a74e0713e846f52264cd21cb7c56fde74c173d615e95c08eb4fc6eee5751fecc32ed31daf3e27f4ad168d8a9404db6635c4d35860ee5daa0dbc7d5b3",
      "line": 240,
      "relation": "decreases",
      "source": 1,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Interestingly, we found a significant reduction in the expression of amyloid plaque associated phospho-p65 NFκB immunopositive cells in Tg PS1/APPswe mice treated with anatabine at either 10 or 20 mg/Kg/Day (Fig 7B) showing that anatabine prevents NFκB activation in the brain of Tg PS1/APPswe mice.",
      "key": "89e52faffd5249dfe4ee7680d9672b70913ac1e2dd6b6b366725109ea77e3d34133d7b06c43d7819fed1aaf4ae260bebeee9d7199f66a128ea2540ef9f9b451a",
      "line": 267,
      "relation": "decreases",
      "source": 1,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We observed that anatabine reduces brain Aβ burden both in the cortex and the hippocampus of Tg PS1/APPswe mice using immunostaining with the antibody 4G8 which recognizes Aβ (Fig 8A and 8B).",
      "key": "e1cac5b5cd19480dc467b8c43c4e90c91e062c2501c894861fab3a4009b70587dcfcf7f728d81ecd2a4a6ccf3d8e2b30ab4feb87984011c518501c97690417c9",
      "line": 280,
      "relation": "decreases",
      "source": 1,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Additionally, we found that Bace1 mRNA expression is significantly increased in the brain of Tg PS1/APPswe mice compared to wild- type littermates, whereas a significant reduction in Bace1 mRNA levels is observed in Tg PS1/ APPswe receiving 20 mg/Kg/Day of anatabine in their drinking water showing that at this dosage anatabine can mitigate the upregulation of Bace1 expression in Tg PS1/APPswe mice (Fig 9).",
      "key": "8dd7572c05f24ace6093b68216ad8655c363bba4b045c03d3b18fbafff0f514f0f4515b290c492e91c238d837767396d0d851c182a163ba416d61449195a415e",
      "line": 296,
      "relation": "decreases",
      "source": 1,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We found a significant reduction in Cox-2 mRNA expression in Tg PS1/ APPswe mice treated with anatabine at a dosage of 20 mg/Kg/Day (Fig 10).",
      "key": "4d093101c280c7c0d79368df14586a8607beba5fb891d368b370a712c0f86ae9e3130ce6f27035466f6b1e2ed9fd28870cc9c865456f745ad42b8d9f5754240f",
      "line": 308,
      "relation": "decreases",
      "source": 1,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "A dose dependent suppression of iNOS transcription was observed in Tg PS1/APPswe mice treated with anata- bine at a dosage of 10 or 20 mg/Kg/Day compared to untreated Tg PS1/APPswe mice (Fig 10).",
      "key": "3c4958d29de7fe4c62a0a8e75390985f84a9daccd56d74b0eb3ffdcd7d2bf1cc7485f7a84b852ebf16977286eeb12419b1edbb3a61108c22ccc39867adf8b57f",
      "line": 319,
      "relation": "decreases",
      "source": 1,
      "target": 20
    },
    {
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48",
      "relation": "hasVariant",
      "source": 9,
      "target": 10
    },
    {
      "key": "df61ed2da577b59eb476b20014b48ce7dddc46a8b052bfee722864042284262027b8c7634f1ed9286e958c8bda1591d3a0bccab4e303ff153371fe48d0f9624b",
      "relation": "hasMember",
      "source": 14,
      "target": 8
    },
    {
      "key": "9f1443e4169985c94f3ec2c5ee081281e5de01be5dde9198f7c54ebbbbbcffa8ffc8b65cfdfbeaa99a0e7f2667997494318d04d75deec58d3287cc7ed98d95a4",
      "relation": "hasVariant",
      "source": 5,
      "target": 6
    },
    {
      "key": "e39435c1348f217cc9cce7c925f90bd391da1bbc939ac4f4c08ca5c70e03100d1a8991a2f918452e95def9067c56d70330d08e862245632e0dbc00b78b74773a",
      "relation": "hasVariant",
      "source": 12,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Transgenic mouse models of AD overexpressing Aβ peptides generally show greater locomotor activity and disinhibition in the elevated plus maze compared to non-transgenic mice, suggest- ing hyperactivity and a lower level of anxiety [28–30]. ",
      "key": "1ee7eb018be76ddac6b56618dee5471b2b1e262b5c87e3bf0de0245fb76ad24389ea8d7bb0e46facf6aee8933eed80bed3768d5ad0d032250ce38967ea5f6849",
      "line": 109,
      "relation": "increases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Transgenic mouse models of AD overexpressing Aβ peptides generally show greater locomotor activity and disinhibition in the elevated plus maze compared to non-transgenic mice, suggest- ing hyperactivity and a lower level of anxiety [28–30]. ",
      "key": "d3c4bdbaa51b54e20445b22ff5341a949f8d40589cae2b23ddabac0d329961ff517f5396b6410e434dae4cbb410c0e1a25fea66e70b81c18045916ab52a84571",
      "line": 110,
      "relation": "decreases",
      "source": 0,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Unlike wild-type mice, Tg PS1/APPswe mice elicited social interaction deficits and spent an equal amount of time in the chamber containing the empty cage or the chamber containing the unfamiliar (Stranger 1) mouse (Fig 4A). Anatabine at a dosage of 20mg/Kg/Day restored sociability in Tg PS1/APPswe mice as Tg PS1/APPswe mice treated with anatabine spent significantly more time in the chamber containing the unfamiliar mouse (Stranger 1) and less time in the chamber containing the empty cage (Fig 4B).",
      "key": "0b69473f5d416d4fe5e24f74328975edacd278b00f2406d394c0447e0d3384ea9be541e00a67440a12a229e0c4009467b04f7db162a290e3393c26c8986ce654",
      "line": 144,
      "relation": "association",
      "source": 0,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " A significant increase in Iba-1 bur- den was observed in the cortex and hippocampus of Tg PS1/APPswe mice compared to their control wild-type littermates, suggesting increased Iba-1 immunopositive microglia in the brain of Tg PS1/APPswe mice (Fig 5A). ",
      "key": "63573de12e48f863205c4092e87050e7521c06b2a5d880ebf3563357048e0cdb558abcd5018bc8e0ea1adcac901a5e51be6f13446f255e57ca1ff781854a3cc0",
      "line": 158,
      "relation": "increases",
      "source": 0,
      "target": 7
    },
    {
      "annotations": {
        "Cell": {
          "macrophage": true,
          "microglial cell": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "A significant increase in CD45 immunopositive microglia/macrophage was observed in the cortex of Tg PS1/APPswe mice compared to wild- type mice (CD45 immunonegative) (Fig 5C). ",
      "key": "6030376f720d4265a17008e774a0b12b135b95b6c8e191462a9e569af6cb4009ee6d04b418f27ff976686a54cc91bb506a14b8c9d2e068de94b2629f85e28a38",
      "line": 187,
      "relation": "increases",
      "source": 0,
      "target": 11
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We observed an elevation of STAT3 phosphorylation in the hippocampus and cortex of Tg PS1/ APPswe compared to their control wild-type littermates (Fig 6A). ",
      "key": "4d31267ad5a32fa6edbad4186ad3b44d3077802f710c71b24076c9473c4e49e044f66ce1f51dc0e15a9309489a3aa192b843d12a9a97b155d3fb8c3d048ced1a",
      "line": 226,
      "relation": "increases",
      "source": 0,
      "target": 13
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "We also observed elevation of NFκB activation in the vicinity of Aβ deposits in the brain of Tg PS1/APPswe mice (Fig 7A).",
      "key": "7f24aa6973a90d29075a38707f423e0ddba3ac2694cacc8f84f7484cf41060dc476a4e5ce5ddddaea2196afbebfdaa3811a13b1df310ff2e2114dbbf16fec6e1",
      "line": 252,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 0,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Additionally, we found that Bace1 mRNA expression is significantly increased in the brain of Tg PS1/APPswe mice compared to wild- type littermates, whereas a significant reduction in Bace1 mRNA levels is observed in Tg PS1/ APPswe receiving 20 mg/Kg/Day of anatabine in their drinking water showing that at this dosage anatabine can mitigate the upregulation of Bace1 expression in Tg PS1/APPswe mice (Fig 9).",
      "key": "31ecacf30470aa911f7988b09c2a738d2a6ec3f72b7e19a35431aebfecfbff8fcadbd49a122b7f311aa4358f74bac8ecd1b45f7e91aab4b1eff653ee39ad9ac3",
      "line": 295,
      "relation": "increases",
      "source": 0,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": "Unlike wild-type mice, Tg PS1/APPswe mice elicited social interaction deficits and spent an equal amount of time in the chamber containing the empty cage or the chamber containing the unfamiliar (Stranger 1) mouse (Fig 4A). Anatabine at a dosage of 20mg/Kg/Day restored sociability in Tg PS1/APPswe mice as Tg PS1/APPswe mice treated with anatabine spent significantly more time in the chamber containing the unfamiliar mouse (Stranger 1) and less time in the chamber containing the empty cage (Fig 4B).",
      "key": "6b717fcee2adc2bff9e7d405cc8e128b153a82bf6a63d24d8c95c92f80dd436a6e1550c2aaf7dcd1a66f781e967cb659066f436212cbbab75dd0e50e9dd01f04",
      "line": 144,
      "relation": "association",
      "source": 15,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " A significant increase in Iba-1 bur- den was observed in the cortex and hippocampus of Tg PS1/APPswe mice compared to their control wild-type littermates, suggesting increased Iba-1 immunopositive microglia in the brain of Tg PS1/APPswe mice (Fig 5A). ",
      "key": "ab2960221aaa00d41e44a0255f13474973a6c8fbe238be48ae9e064cdb608a4286dddee01143ab682b425a86710b9c71e0377b655409bbc20297cb16d8f2a77a",
      "line": 159,
      "relation": "positiveCorrelation",
      "source": 7,
      "target": 3
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " A significant increase in Iba-1 bur- den was observed in the cortex and hippocampus of Tg PS1/APPswe mice compared to their control wild-type littermates, suggesting increased Iba-1 immunopositive microglia in the brain of Tg PS1/APPswe mice (Fig 5A). ",
      "key": "b774f8c7996462a0bc2fcaf209cf019114e7b552274522f3ea8ecc6bea9c3b14fd4fd672302df5a28845724de3478a730aefacd18c374dfeeb291673182a2a8c",
      "line": 159,
      "relation": "positiveCorrelation",
      "source": 3,
      "target": 7
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Interestingly, we found a significant reduction in the expression of amyloid plaque associated phospho-p65 NFκB immunopositive cells in Tg PS1/APPswe mice treated with anatabine at either 10 or 20 mg/Kg/Day (Fig 7B) showing that anatabine prevents NFκB activation in the brain of Tg PS1/APPswe mice.",
      "key": "9dbf27c913917224dc2fb8609ae5c2830617036c30b1fb985690694c7728ae64bd6a51de51c1a73697514dfc26dffb7079dd27f7f5b6b2b37a0e3563d5527f39",
      "line": 266,
      "relation": "association",
      "source": 16,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "Medium": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Ait-Ghezala G",
          "Beaulieu-Abdelahad D",
          "Crawford F",
          "Li R",
          "Mullan M",
          "Paris D",
          "Verma M"
        ],
        "date": "2015-01-01",
        "first": "Verma M",
        "last": "Paris D",
        "name": "PloS one",
        "pages": "e0128224",
        "reference": "26010758",
        "title": "Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.",
        "type": "PubMed",
        "volume": "10"
      },
      "evidence": " Interestingly, we found a significant reduction in the expression of amyloid plaque associated phospho-p65 NFκB immunopositive cells in Tg PS1/APPswe mice treated with anatabine at either 10 or 20 mg/Kg/Day (Fig 7B) showing that anatabine prevents NFκB activation in the brain of Tg PS1/APPswe mice.",
      "key": "5875d856ac2674fa2708f3db5ef0503ae4b094db75c3df6a6a689d583fa5ac9c4d496769874909d6193962462ff75ab846f45b3e518a2e36d21e7e41e755dc39",
      "line": 266,
      "relation": "association",
      "source": 6,
      "target": 16
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "function": "Abundance",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2",
      "name": "amyloid-beta",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:Anatabine)",
      "function": "Abundance",
      "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6",
      "name": "Anatabine",
      "namespace": "CHEBI"
    },
    {
      "bel": "bp(GO:\"inflammatory response\")",
      "function": "BiologicalProcess",
      "id": "422dfc2db00b1d942862470cbabe1e8312bf97b25050190db5ae19636adae95f4fa18c512574526825bd377b16c2278899435eb759e951ba850ad476e14f9900",
      "name": "inflammatory response",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"microglial cell activation\")",
      "function": "BiologicalProcess",
      "id": "9e9682b78aa06bbcb9dae35006f6da468e11928c000097001cd665b1bedf3c75ef887ecd7781ef3c545cafb3780cb7afabec9bfc70e14a48149d8adee8502981",
      "name": "microglial cell activation",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:locomotion)",
      "function": "BiologicalProcess",
      "id": "e39e344818f1c8be3c26236deebbb894a1271eb3c094358751fb6cb220c0e74e1b41c6bb643891cb9835caff7f7a07e32061891beccec54ccee5cfb83b59e23e",
      "name": "locomotion",
      "namespace": "GO"
    },
    {
      "bel": "p(FPLX:NFkappaB)",
      "function": "Protein",
      "id": "a76f3010d13c4b506ba95e6e6bef897dc400ea1bad5f8288ce4b084f2b57f9e7aa59f5146eff656ed56a6d2077d5907c41cbd4539f26d63411b79ffe7179e54a",
      "name": "NFkappaB",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:NFkappaB, pmod(Ph, Ser, 536))",
      "function": "Protein",
      "id": "998a342381584147b27fb34596cbb2f5ca3ba1c553214a0a8c98cfea48b7cec77631f0793c6ab957f63f968ece79416b9cee956f391424aec18d81297eed48e9",
      "name": "NFkappaB",
      "namespace": "FPLX",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 536
        }
      ]
    },
    {
      "bel": "p(HGNC:AIF1)",
      "function": "Protein",
      "id": "da3f4ed960bc9dd7ae753d2f485b59837ac03a6889148a2618157a8dbbd1043a57d436425bc9fab7b74b2cccd429bbdc16cf949017eab924a6743442a8af19a4",
      "name": "AIF1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:CHRNA7)",
      "function": "Protein",
      "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99",
      "name": "CHRNA7",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "function": "Protein",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
      "name": "MAPT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "function": "Protein",
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:PTPRC)",
      "function": "Protein",
      "id": "b07516f534f0eb04810cf470ff3559943ee41e0a70eeda6d99f4278b1dd9d81efb4d7044b755c7a4258d520452fa564e47ad4ea67cec2879b9f60f98d6a75398",
      "name": "PTPRC",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:STAT3)",
      "function": "Protein",
      "id": "3127bcd18ece964c797c6ae9fcf716d99ad750c12e3f8121f817efbbedc60af9639294ab059c32ef6101cef3ccd9abc934d90dc7ccdbe6dc3604773782f7bf97",
      "name": "STAT3",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:STAT3, pmod(Ph))",
      "function": "Protein",
      "id": "e77397464fb83748a7286fed66311fda660971f8d0f47f6e1290ea5f6857bdf68d361fd34f0055467a45dd0e21d8008bba9648e146ffd83670ee544b04bcf8d4",
      "name": "STAT3",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "function": "Protein",
      "id": "d55bebfe65f49c8e66d1ed0b491af0f01aba4b030a649599e59150e53ed4d3e4cd2199be8863b95c7033ab2185d8d7ea9203e5418faea9d7dcc86757b9bcf4dd",
      "name": "Cholinergic receptors nicotinic subunits",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "path(MESH:\"Interpersonal Relations\")",
      "function": "Pathology",
      "id": "311d2db3d681b4d769dcee208e2f77603dae784f5182c4f5a7c3b8488515a55e20c154148cebea719d50c2a0fbe9ce565ec6d51e202e4668d95ce5019b0726d7",
      "name": "Interpersonal Relations",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Plaque, Amyloid\")",
      "function": "Pathology",
      "id": "888c33ecabc995942e605aace0106831b95c6e6d4eb99ee4ac4c1de25ff7c58c0cb67b5e941c2d3f3a399aada51a34de03850a43011389d2ab7dae07536cea30",
      "name": "Plaque, Amyloid",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Anxiety)",
      "function": "Pathology",
      "id": "28f6f3390e4ae722f1c1298abe2059a3e03a8a2de93e506a747733d9e980ed28bb2feb1074ec430fda167d3f38e3c1d930e10c16e5e04f371938ce866caba0dc",
      "name": "Anxiety",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Gliosis)",
      "function": "Pathology",
      "id": "46d8ab84a7ce6995389ca278324930486e96f976926c8cc7fe6a9d293d79524be3010be1e4a9cb2975094b5fe03efce5bb8a536051d0ca1cb100da38c5f62c6f",
      "name": "Gliosis",
      "namespace": "MESH"
    },
    {
      "bel": "r(HGNC:BACE1)",
      "function": "RNA",
      "id": "7a8568c6a73744c08bc8ed3703f3eef2f933911dbe9dae8311ac46e3d08142e14304751f4daec9b68714f7c8b28ec250df2e1ed4f91bd3469c309a95e46b89b4",
      "name": "BACE1",
      "namespace": "HGNC"
    },
    {
      "bel": "r(HGNC:NOS2)",
      "function": "RNA",
      "id": "7c222d0f52c095955fc94c99a5af35d2a66c44534ef1674028745751155eccff567b75acf75e0d26b54c30cf2da5a07d8949f65e2ce54cde139969a5e120a761",
      "name": "NOS2",
      "namespace": "HGNC"
    },
    {
      "bel": "r(HGNC:PTGS2)",
      "function": "RNA",
      "id": "599879a7226c3e6205b226f58d85bc873329f79e06e190650f1de814b36acb3da9b0b2750c61728b51085926d46fe5de80e65aa9ceac5989eed943823f1cb82b",
      "name": "PTGS2",
      "namespace": "HGNC"
    }
  ]
}